Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01701076
Recruitment Status : Completed
First Posted : October 4, 2012
Last Update Posted : August 24, 2016
Celgene Corporation
Mundipharma Research GmbH & Co KG
Mundipharma Medical Company
Information provided by (Responsible Party):
PD Dr. Ulrich Mey, Kantonsspital Graubünden

September 27, 2012
October 4, 2012
August 24, 2016
March 2012
February 2016   (Final data collection date for primary outcome measure)
Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen [ Time Frame: Every 4 weeks up to 7 months ]
Same as current
Complete list of historical versions of study NCT01701076 on Archive Site
  • Objective response rates (sCR, CR, VGPR, PR, MR) [ Time Frame: Every 4 weeks up to 7 months ]
  • Best response (sCR, CR, VGPR, PR, MR) [ Time Frame: Every 4 weeks up to 36 months ]
  • Time to progression (TTP) [ Time Frame: Every 4 weeks up to 36 months ]
  • Overall survival (OS) [ Time Frame: Every 8 weeks up to 36 months ]
  • Safety and tolerability [ Time Frame: Every 4 weeks until 30 days after completion of study treatment ]
    • Type, frequency, severity, and relationship of adverse events to study therapy
    • According to NCI CTCAE v4.0
Same as current
Not Provided
Not Provided
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Almost all patients with multiple myeloma who survive initial treatment will eventually relapse and require further therapy.

Background: Treatment with lenalidomide and dexamethasone has proven efficacy in two large randomized trials (MM-009 and MM-010) leading to a time to progression (TTP) of 17.1 months for patients with only one prior therapy and a TTP of 10.6 months for 2 and more prior therapies, respectively [1-3]. Continuous treatment with lenalidomide and dexamethasone until disease progression is therefore considered a standard therapy for second line treatment in multiple myeloma patients. However, only a relatively low rate of high quality response (CR, complete response and VGPR, very good partial response) is achieved. High quality responses are associated with with improved progression-free survival and overall survival [4].

Trial: The aim of this trial is to improve high quality response rates for patients with relapsed or refractory multiple myeloma in the 2nd line treatment. This aim shall be achieved by the addition a third anti-myeloma drug (bendamustine) to the established backbone of lenalidomide/ dexamethasone.

Treatment regimen:

  • Induction Treatment Phase: Cycles 1-6 Bendamustine 75mg/m2/d day 1 and 2, lenalidomide 25mg/d 1-21, dexamethasone 40mg / 20mg (for patients > 75years) d 1, 8, 15, 22.
  • Maintenance Treatment Phase: Cycles 7-18 lenalidomide 25mg/d 1-21, dexamethasone 40mg / 20mg (for patients > 75 years) d 1, 8, 15, 22.

Due to hematoxicity of bendamustine and lenalidomide, administration of pegfilgrastim is mandatory in the induction treatment phase (BRd-regimen)for all patients experiencing severe neutropenia.

The aim of this study is to achieve high quality response rates (CR, VGPR) of ≥ 40%. If this aim is achieved, the treatment of bendamustine in combination with the established lenalidomide/ dexamethasone regimen will be considered promising.

Besides efficacy, the safety of this three-drug regimen is evaluated in this trial.

Assessments for efficacy / response evaluation:

  • M-protein quantitation in serum and 24 h urine collection samples by serum- and urine protein electrophoresis
  • Quantitation of immunoglobulin levels by nephelometry
  • Serum and urine immunofixation
  • Free light chain concentrations and ratio in the serum
  • Plasma cell percentage in the bone marrow by conventional cytology and biopsy with immunohistochemistry
  • Radiologic assessments of the skeleton

Response criteria: Response will be assessed according to IMWG criteria

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Multiple Myeloma
Drug: Bendamustine

Induction treatment phase (cycle 1-6):

  • Bendamustine 75 mg/m2 i.v day 1 and 2
  • Lenalidomide 25 mg p.o. day 1-21
  • Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
  • Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia

Maintenance treatment phase (cycles 7-18):

  • Lenalidomide 25 mg p.o. day 1-21
  • Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
Other Names:
  • Lenalidomide
  • Dexamethasone
  • Pegfilgrastim
Experimental: Bendamustine
All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
Intervention: Drug: Bendamustine

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
February 2016
February 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent
  • Patients with first relapsed or refractory multiple myeloma (including patients with relapse after high dose chemotherapy followed by autologous stem cell transplantation) who have received no more than one prior line of anti-myeloma treatment
  • Treatment with a lenalidomide/ dexamethasone-based 2nd-line regimen is indicated and intended
  • Measurable disease as defined by at least one of the following 3 measurements

    • serum monoclonal protein level ≥ 1 g/dl (≥ 10 g/l) or
    • urine M-protein level ≥ 200 mg/24hours or
    • serum FLC assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l) provided serum FLC ratio is abnormal
  • ECOG performance status 0, 1, or 2
  • Age ≥ 18 years
  • All previous cancer therapy (except corticosteroid therapy), including radiation, cytostatic therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
  • No prior treatment with a bendamustine-containing regimen allowed
  • Prior treatment with lenalidomide is allowed if the treatment is completed > 12 month prior to study entry and the patient responded to prior lenalidomide treatment
  • Adequate hematological values:

    • absolute neutrophil count ≥ 1.5 x 109/L
    • platelets ≥ 100 x 109/L
    • hemoglobin > 80 g/L, unless considered to be caused by the underlying hematologic malignancy, based on the investigator's clinical judgement
  • Adequate hepatic function:

    • total bilirubin < 1.2 mg/dL
    • AST (SGOT) ≤ 2.5 x ULN
  • Adequate renal function:

    o calculated creatinine clearance > 50 ml/min, according to the formula of Cockcroft-Gault

  • Disease free of prior malignancies for > 5 years unless the patient

    • has been treated with a curative intent and is considered to be in complete remission for ≥2 years prior to study enrolment
    • or has a curatively-treated

      • basal cell/ squamous cell carcinoma of the skin,
      • carcinoma "in situ"of the cervix,
      • ductal breast carcinoma in situ with complete surgical resection (i.e. negative margins),
      • medullary or papillary thyroid tumor
      • or low grade, early stage localized prostate cancer treated surgically with curative intent

Exclusion Criteria:

  • Pregnant or breast feeding females
  • Any prior use of bendamustine
  • Patients who are unable or unwillingly to undergo antithrombotic therapy
  • Any serious underlying medical condition (at the judgment of the investigator) which impairs the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorder)
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she would participate in the study or any condition significantly confounding the ability to interpret data from the study, based on the local investigator's judgement
  • Severe cardiovascular disease, including myocardial infarction within 6 months before study entry, New York Heart Association Class III or IV heart failure, uncontrolled angina or severe uncontrolled ventricular arrhythmias (≥ Lown 3)
  • Use of any other experimental drug or therapy/ treatment in a clinical trial within 30 days prior to trial entry
  • Known hypersensitivity to study drug(s) or hypersensitivity to any other component of the study drugs
  • Any concurrent antineoplastic therapy with chemotherapeutic agents or biologic agents or radiation therapy
  • Any major surgical procedure within 30 days prior to study therapy
  • Known chronic hepatitis B or C, known HIV infection
  • Jaundice or any other severe damage of the liver parenchyma
  • Any contraindication for the treatment with bendamustine, lenalidomide, dexamethasone and / or pegfilgrastim in accordance with the appropriate SmPCs
  • Any other concomitant drugs contraindicated for use with the study drugs according to the national health authorities
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
2010-022253-42 ( EudraCT Number )
Not Provided
Not Provided
PD Dr. Ulrich Mey, Kantonsspital Graubünden
Cantonal Hospital of St. Gallen
  • Celgene Corporation
  • Mundipharma Research GmbH & Co KG
  • Mundipharma Medical Company
  • Amgen
Study Chair: Ulrich Mey, MD Kantonsspital Graubünden
Cantonal Hospital of St. Gallen
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP